Skip to main content
Hemostemix Inc. logo

Hemostemix Inc. — Investor Relations & Filings

Ticker · HEM ISIN · CA4236943060 LEI · 984500C65BB0B8159L77 TSXV Professional, scientific and technical activities
Open in API
Filings indexed 576 across all filing types
Latest filing 2026-05-13 Regulatory Filings
Country CA Canada
Listing TSXV HEM

About Hemostemix Inc.

https://hemostemix.com/

Hemostemix Inc. is a clinical-stage biotechnology company specializing in regenerative medicine through the development and commercialization of autologous (patient's own) blood-derived stem cell therapies. The company's lead investigational product is ACP-01 (Angiogenic Precursor Cell treatment), a platform targeting ischemic conditions such as Critical Limb Ischemia (CLI), ischemic cardiomyopathy, and angina. ACP-01 is designed to address unmet medical needs, particularly in patients ineligible for standard revascularization procedures. Phase II clinical data re-examination for "no option" CLI indicated that ACP-01 administration was safe and associated with reduced ulcer size and decreased rates of amputation and death.

Recent filings

Filing Released Lang Actions
Notice of the meeting and record date (amended) - English.pdf
Regulatory Filings Classification · 70% confidence The document is a formal notice to Canadian Securities Regulatory Authorities advising that the upcoming Annual General and Special Meeting has been cancelled. It does not contain meeting materials or financial data, nor is it a proxy statement or vote result. It is a general regulatory announcement, fitting the fallback category for miscellaneous filings.
2026-05-13 English
52-109FV1 - Certification of annual filings - CFO (E).pdf
Regulatory Filings
2026-05-01 English
Annual MD&A - English.pdf
Regulatory Filings
2026-05-01 English
AB form 13-501F1 (class 1 and 3B reporting issuers - participation fee).PDF
Regulatory Filings
2026-05-01 English
Audited annual financial statements – English.pdf
Regulatory Filings
2026-05-01 English
Notice of the meeting and record date - English.pdf
Proxy Solicitation & Information Statement Classification · 80% confidence The document is a formal notice to securities regulators outlining the details of an upcoming Annual General and Special Meeting (record dates, meeting date, format, voting security details). It is part of the proxy solicitation process—providing information to facilitate shareholder voting. There is no financial result, legal proceeding, or report attached, so it fits the Proxy Solicitation & Information Statement category.
2026-04-09 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.